Please provide your email address to receive an email when new articles are posted on . High hematocrit levels were observed among 8.4% of adults receiving gender-confirming testosterone therapy.

SAN DIEGO -- A novel therapy for polycythemia vera (PCV) maintained stable hematocrit levels for as long as 2.5 years and significantly reduced use of phlebotomy, a small randomized trial showed. The ...

Credit: Thinkstock. The risk of hematocrit elevation may depend on testosterone therapy's route of administration, according to investigators. A rise in hematocrit levels occurs with 4 months of ...

The use of testosterone as gender-affirming hormone therapy (GAHT) among transgender men is associated with a lower risk for erythrocytosis (abnormal blood cell elevation) than was previously reported ...

Researchers explored the incidence of erythrocytosis in the first 20 months of testosterone therapy among people receiving gender-affirming hormone therapy (GAHT). Specifically, they conducted a ...

Please provide your email address to receive an email when new articles are posted on . Aaron T. Gerds, MD, MS, spoke with Healio about the REVEAL study, results of which were presented at this year’s ...

ORLANDO, Fla. — Rusfertide, a weekly self-injected peptide, maintained control of hematocrit levels and reductions in phlebotomy requirements through 52 weeks in patients with polycythemia vera (PV), ...

The decision as to when to give blood transfusions is complex, requiring a careful assessment of risks and benefits. The TRACS trial compared the effects of giving blood transfusions perioperatively ...

Rusfertide effectively maintains hematocrit control and reduces phlebotomy need in PV patients, as shown in the VERIFY study over 52 weeks. The therapy, a hepcidin mimetic peptide, regulates iron ...

LONDON--(BUSINESS WIRE)--Silence Therapeutics plc (“Silence” or the “Company”) (Nasdaq: SLN), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced ...